Purine metabolism pathway (null)

The purine metabolism pathway describes the collection of enzymatic processes responsible for the synthesis (de novo and salvage), breakdown (catabolism), and recycling of purine nucleotides, including adenine and guanine bases. Synthesis is a multi-step, energy-intensive process using precursors like amino acids (glutamine, glycine, aspartate), formate, and ribose-5-phosphate via enzymes such as amidophosphoribosyltransferase, GAR synthetase, and IMP dehydrogenase[1][5][6]. Catabolism involves the degradation of purine nucleotides to uric acid in humans, with multiple enzymatic steps and regulatory mechanisms. Therapeutic intervention in purine metabolism typically targets specific enzymes within the pathway (e.g., by antimetabolites like 6-mercaptopurine and methotrexate) to disrupt DNA/RNA synthesis, particularly in rapidly dividing cells as seen in cancer and immune disorders[2][4][6]. However, 'purine metabolism pathway' itself does not represent a single canonical druggable target, but rather a pathway encompassing multiple potential targets[2][4][6]. Key Limitation: 'Purine metabolism pathway' is not a standard or canonical drug target. Rather, it refers to a broad biochemical network. When referencing drug targets, it is more scientifically appropriate to specify individual enzymes (e.g., IMP dehydrogenase, amidophosphoribosyltransferase, etc.) within this pathway[4][5][6].

Other names

Purine metabolic pathwayPurine biosynthesis and degradationPurine nucleotide metabolism

Enzyme inhibition (e.g., inhibition of IMP dehydrogenase, GART, or amidophosphoribosyltransferase), Antimetabolite incorporation